136 related articles for article (PubMed ID: 28747781)
1. Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model.
Bu LL; Li YC; Yu GT; Liu JF; Deng WW; Zhang WF; Zhang L; Sun ZJ
Sci Rep; 2017 Jul; 7(1):6629. PubMed ID: 28747781
[TBL] [Abstract][Full Text] [Related]
2. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
Soleimani AH; Garg SM; Paiva IM; Vakili MR; Alshareef A; Huang YH; Molavi O; Lai R; Lavasanifar A
Drug Deliv Transl Res; 2017 Aug; 7(4):571-581. PubMed ID: 28290050
[TBL] [Abstract][Full Text] [Related]
3. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.
Park JW; Han CR; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408
[TBL] [Abstract][Full Text] [Related]
5. Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.
Kumar G; Goldberg SN; Gourevitch S; Levchenko T; Torchilin V; Galun E; Ahmed M
Radiology; 2018 Feb; 286(2):524-536. PubMed ID: 28880787
[TBL] [Abstract][Full Text] [Related]
6. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.
Siddiquee K; Zhang S; Guida WC; Blaskovich MA; Greedy B; Lawrence HR; Yip ML; Jove R; McLaughlin MM; Lawrence NJ; Sebti SM; Turkson J
Proc Natl Acad Sci U S A; 2007 May; 104(18):7391-6. PubMed ID: 17463090
[TBL] [Abstract][Full Text] [Related]
7. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.
Pang M; Ma L; Gong R; Tolbert E; Mao H; Ponnusamy M; Chin YE; Yan H; Dworkin LD; Zhuang S
Kidney Int; 2010 Aug; 78(3):257-68. PubMed ID: 20520592
[TBL] [Abstract][Full Text] [Related]
8. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
[TBL] [Abstract][Full Text] [Related]
9. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Mouw KW; Cleary JM; Reardon B; Pike J; Braunstein LZ; Kim J; Amin-Mansour A; Miao D; Damish A; Chin J; Ott PA; Fuchs CS; Martin NE; Getz G; Carter S; Mamon HJ; Hornick JL; Van Allen EM; D'Andrea AD
Clin Cancer Res; 2017 Jun; 23(12):3214-3222. PubMed ID: 27852700
[No Abstract] [Full Text] [Related]
10. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent.
Ball DP; Lewis AM; Williams D; Resetca D; Wilson DJ; Gunning PT
Oncotarget; 2016 Apr; 7(15):20669-79. PubMed ID: 26942696
[TBL] [Abstract][Full Text] [Related]
11. Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Anticancer Res; 2014 Nov; 34(11):6537-45. PubMed ID: 25368256
[TBL] [Abstract][Full Text] [Related]
12. S3I-201, a selective Stat3 inhibitor, restores neuroimmune function through upregulation of Treg signaling in autistic BTBR T
Ahmad SF; Ansari MA; Nadeem A; Bakheet SA; Alshammari MA; Khan MR; Alsaad AMS; Attia SM
Cell Signal; 2018 Dec; 52():127-136. PubMed ID: 30213685
[TBL] [Abstract][Full Text] [Related]
13. S3I-201 ameliorates tubulointerstitial lesion of the kidneys in MRL/lpr mice.
Du Y; Zhang W; Liu S; Feng X; Gao F; Liu Q
Biochem Biophys Res Commun; 2018 Sep; 503(1):177-180. PubMed ID: 29885836
[TBL] [Abstract][Full Text] [Related]
14. The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy.
Martin D; Rödel F; Balermpas P; Rödel C; Fokas E
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):221-230. PubMed ID: 28501560
[TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
Ko HJ; Kim YJ
Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
17. Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC.
Fan TF; Bu LL; Wang WM; Ma SR; Liu JF; Deng WW; Mao L; Yu GT; Huang CF; Liu B; Zhang WF; Sun ZJ
Oncotarget; 2015 Dec; 6(41):43581-93. PubMed ID: 26561201
[TBL] [Abstract][Full Text] [Related]
18. Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.
Scheper MA; Nikitakis NG; Chaisuparat R; Montaner S; Sauk JJ
Neoplasia; 2007 Mar; 9(3):192-9. PubMed ID: 17401459
[TBL] [Abstract][Full Text] [Related]
19. Anal squamous cell carcinoma - State of the art management and future perspectives.
Martin D; Balermpas P; Winkelmann R; Rödel F; Rödel C; Fokas E
Cancer Treat Rev; 2018 Apr; 65():11-21. PubMed ID: 29494827
[TBL] [Abstract][Full Text] [Related]
20. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
Wang X; Goldstein D; Crowe PJ; Yang M; Garrett K; Zeps N; Yang JL
Oncotarget; 2016 Apr; 7(16):21496-509. PubMed ID: 26909593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
